Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
Clinical trial NCT03664024 · COMPLETED
Trial details
- NCT number
- NCT03664024
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-30
- Primary completion
- 2021-11-05
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.